Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. by Schnabl, Bernd et al.
  
Introduction 
 
The Kruppel-like transcription factor (KLF) family 
is involved in the regulation of diverse aspects 
of cellular development, differentiation, growth, 
and activation [1]. KLFs contain multiple zinc 
fingers, which represent one of the most com-
mon DNA binding domains. A zinc finger con-
tains two cysteine and two histidine residues 
that coordinate a single zinc ion and fold the 
domain into a finger-like projection [2]. Seven-
teen mammalian KLFs have been identified and 
some of them have been recognized to be in-
volved in numerous disorders such as cancer, 
obesity, cardiovascular disease, and inflamma-
tory conditions [1].  
 
KLF proteins are also involved in the develop-
ment and progression of different chronic liver 
disease. For example, Kruppel-like factor 15 
activates hepatitis B virus gene expression and 
replication [3]. KLF8 is up-regulated in hepato-
cellular cancer (HCC), promotes tumour inva-
sion and indicates a poor prognosis for patients 
with liver cancer [4]. In contrast, KLF6 (also 
named human zinc finger 9 (ZF9) or COPEB) is a 
tumor suppressor gene for HCC [5,6]. Further-
more, KLF6 is up-regulated in association with 
increased steatosis, inflammation, and fibrosis 
in non-alcoholic fatty liver disease (NAFLD) 
[7,8]. 
 
One further member of the Kruppel-like zinc 
finger family is zinc finger protein 267 (ZNF267; 
also named human zinc finger 2 or HZF2) [9]. It 
contains a conserved Kruppel associated box 
(KRAB) domain in the amino terminal part, 
which is separated through a linker region from 
a clustered zinc finger domain [9]. The first zinc 
finger is followed by three degenerated fingers, 
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and then continues with 13 zinc fingers at the 
carboxy terminus [9]. The function of ZNF267 is 
widely unknown; its mRNA is up-regulated upon 
nitric oxide treatment in venous endothelial 
cells [10], and previously, we have demon-
strated that ZNF267 mRNA is up-regulated in 
liver cirrhosis compared to normal human liver 
tissue [11]. Furthermore, we found that ZNF267 
expression is increased in human HCC-cells and 
tissue compared to primary human hepatocytes 
(PHH) and corresponding non-tumorous hepatic 
liver tissue, respectively [12].  
 
Nonalcoholic fatty liver disease (NAFLD) is today 
recognized as the most common liver disease 
and one of the most frequent causes of liver 
cirrhosis [13,14]. Furthermore, NAFLD is a main 
risk factor for the development and progression 
of HCC [15]. NAFLD is characterized by lipid 
accumulation in the liver that may progress 
from simple hepatic steatosis towards inflam-
mation (non-alcoholic steatohepatitis [NASH]) 
with progressive fibrosis [16,17,18].  
 
NAFLD is strongly associated with the metabolic 
syndrome and its defining pathophysiological 
components obesity, diabetes and dyslipidemia. 
Thus, overeating delivers an excess of triglyc-
erides to the liver. Further, peripheral lipolysis in 
obese and insulin resistant states leads to an 
increased hepatic influx of fatty acids (FA). In 
addition, hepatic FA synthesis is increased sec-
ondary to elevated glucose and insulin levels. 
Together, both uptake of exogenously derived 
FA and de novo hepatic synthesis of FA lead to 
an increase of hepatic lipid content, e.g. hepatic 
steatosis [19,20,21]. 
 
In the present study we aimed to assess the 
effect of hepatic steatosis on ZNF267 expres-
sion in an in vitro model of hepatocellular lipid 
accumulation [22] and in hepatic specimens of 
NAFLD patients.  
 
Materials and methods 
 
Cells and cell culture 
 
Isolation and culture of primary human hepato-
cytes (PHH) were performed as described [23]. 
The HCC cell line HepG2 (ATCC HB-8065) was 
cultured as described previously [24,24]. Hepa-
tocellular lipid accumulation was induced as 
described [25]. Briefly, a 10 mM palmitate/1% 
bovine serum albumin (BSA) stock solution was 
obtained by complexing the appropriate amount 
of palmitate to BSA. PHH were grown in DMEM 
supplemented with penicillin (400 U/ml), strep-
tomycin (50 mg/ml), L-glutamine (300 mg/ml), 
0.2% FCS and palmitate for 24h in different 
concentrations as indicated. FFA-free-BSA-
treated cells served as controls.  
 
To induce ROS formation cells were incubated 
with 10µM arsenic trioxide (As2O3; Sigma Al-
drich) as described [12]. 
 
Human tissue 
 
Human liver specimens from patients were ob-
tained during resection of metastasis of non-
hepatic tumors. Tissue samples were immedi-
ately snap frozen after surgical resection and 
stored at -80°C until subsequent analysis. For 
this study, the following exclusion criteria were 
applied: 1. chronic alcohol abuse (more than 30 
g/day for men and 20g/day for women), 2. 
medications known to cause hepatic steatosis 
(at present or within the last 2 years), 3. signifi-
cant weight loss (more than 3 kg within the last 
3 months), 4. hepatobiliary diseases, 5. ascites 
on ultrasound, 6. inflammatory bowel disease, 
7. infection with the human immunodeficiency 
virus or Hepatitis B and C virus, and 8. chemo-
therapy prior to partial hepatectomy.  
 
Hepatic steatosis and inflammation was scored 
applying a modified histological score according 
to the recommendations of the Nonalcoholic 
Steatohepatitis Clinical Research Network [26]. 
Briefly, four histological features were evaluated 
semi-quantitatively: steatosis (0-3), lobular in-
flammation (0-2), hepatocellular ballooning (0-
2), and fibrosis (0-4). Simple steatosis was diag-
nosed in the presence of steatosis but the ab-
sence of inflammation, fibrosis and hepatocellu-
lar ballooning. Steatohepatitis was diagnosed 
when the sum of the scores was 4 or more. 
 
Human liver tissue was obtained and experi-
mental procedures were performed according to 
the guidelines of the charitable state controlled 
foundation HTCR, with the informed patient's 
consent, and the study was approved by the 
local ethics committee of the University Regens-
burg. 
 
Expression analysis 
 
Isolation of total cellular RNA from cultured cells 
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and tissue and reverse transcription were per-
formed as described previously [27]. Quantita-
tive real-time PCR was performed with primers 
specific for ZNF267 (forward: 5’- ATG GGA GCT 
GTG ATC TTG AGA; reverse: 5’-GCA ATG ATG AAT 
GAG TAA AGA CC), employing LightCycler tech-
nology (Roche, Mannheim, Germany) [28]. 
 
Detection of ROS 
 
Cells were plated in 96-well-plates and cultured 
in DMEM without phenol red (PAN Biotech 
GmbH, Aidenbach, Germany). Three hours after 
treatment with As2O3 or palmitate cells were 
washed with PBS and were incubated for 30min 
at 37°C with the redox-sensitive dye 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA, 
Invitrogen, Darmstadt, Germany; 100μM). Sub-
sequently, ROS formation was detected using a 
multiwell fuorescence plate reader (Spectra 
Fuor Plus, Tecan, Männedorf, Switzerland) with 
excitation and emission filters of 485 and 
535nm, respectively. 
 
Statistical analysis 
 
Statistical analyses were performed using 
GraphPad Prism Software (GraphPad Software, 
Inc., San Diego, USA). Results are expressed as 
mean ± standard error. Comparisons between 
groups were made using the unpaired t-test. P-
values ≤0.05 were considered statistically sig-
nificant. 
 
Results 
 
ZNF267 expression in NAFLD 
 
First, we assessed ZNF267 mRNA levels in liver 
specimens from patients with NAFLD and nor-
mal human liver tissue. Quantitative RT-PCR 
analysis revealed significantly increased 
ZNF267 expression in both simple steatosis 
and NASH compared to non-steatotic liver tis-
sue (Figure 1). ZNF267 mRNA levels did not 
differ significantly between simple steatosis and 
NASH. These findings indicated that hepatocel-
lular lipid accumulation rather than hepatic in-
flammation causes an upregulation of ZNF ex-
pression in NAFLD. 
 
ZNF267 expression in an in vitro model of hepa-
tocellular lipid accumulation 
 
To follow up with this hypothesis, we next ana-
lyzed ZNF267 mRNA expression in an in vitro 
model of hepatocellular lipid accumulation 
which we have recently described [22]. In this 
model incubation of primary human hepato-
cytes (PHH) with palmitate leads to a dose de-
pendent cellular lipid accumulation [22]. Palmi-
tate (C16:0) is the most abundant saturated 
fatty acid in the human diet, and the major one 
synthesized de novo [29,30]. Increasing doses 
of palmitate caused a dose-dependent increase 
of ZNF267 expression in PHH (Figure 2a). Simi-
larly, lipid accumulation can be induced in the 
hepatoma cell line HepG2 [22], and also here, 
steatosis caused increased ZNF267 expression 
(data not shown). In line with previous reports 
[31,32,33], we detected increased ROS forma-
tion in response to palmitate stimulation in 
HepG2 cells (Figure 2b). Arsenic acid is a chemi-
cal inducer of ROS formation [34] (Figure 2b), 
and stimulation of HepG2 cells with Arsenic acid 
leads to a marked increase of ZNF267 expres-
sion (Figure 2c). Together these findings indi-
cate that ROS formation is at least one mecha-
nism by which hepatocellular lipid accumulation 
increases ZNF267 expression. 
 
Discussion 
 
The aim of this study was to investigate the ex-
pression and function of ZNF267 in non-
alcoholic fatty liver disease (NAFLD). Assess-
Figure 1. ZNF267 expression in NAFLD: Expression 
of ZNF267 mRNA in normal, non steatotic human 
liver tissue compared to steatotic liver tissue without 
inflammation and NASH specimens analyzed by 
quantitative real-time PCR (*:p<0.05 compared to 
normal liver tissue). 
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ment of human liver specimens revealed that 
ZNF267 mRNA levels were significantly higher 
in NAFLD compared to normal hepatic tissue. 
Interestingly, ZNF267 mRNA levels did not differ 
significantly between simple steatosis and 
NASH. These findings indicate that hepatocellu-
lar lipid accumulation and not inflammation is 
the inducer of ZNF267 gene transcription in 
NAFLD. In accordance, incubation of primary 
human hepatocytes with palmitic acid induced a 
dose-dependent upregulation of ZNF267 ex-
pression. In line with previous studies 
[31,32,33] we observed considerable ROS for-
mation in response to the hepatocellular lipid 
accumulation, and moreover, we demonstrated 
that also chemically induced ROS formation led 
to a marked upregulation of ZNF267 mRNA ex-
pression in hepatoma cells. Most recently, we 
have identified the transcription factor Ets-1 as 
key regulator of basal as well as induced 
ZNF267 expression in liver cancer cells [12], 
and the release of free radicals as ROS has 
been shown to induce the transcription of Ets-1 
in tumor cells [35]. In summary, these findings 
suggest that ROS-induced Ets-1 activation is at 
least one loop by which hepatic steatosis in-
duces ZNF267 expression. With regards to this, 
we recently demonstrated that ZNF267 pro-
motes proliferation and migration of HCC cells 
[12], and further, that Ets-1 is strongly linked to 
HCC progression [36,37,38]. Moreover, we have 
recently shown that ZNF267 promotes tumori-
genicity of HCC cells in vitro [12]. Together 
these findings indicate that enhanced ZNF267 
expression may be at least part of the mecha-
nisms by which Ets-1 exhibits its pro-
cancerogenic effect in NAFLD. Furthermore, it 
has to be once more emphasized that ZNF267 
expression is already increased in steatotic liv-
ers in the absence of inflammation. This further 
underscores that simple steatosis cannot be 
considered as benign but per se is a risk factor 
for HCC development and progression [15]. Fur-
thermore, it has to be considered that ZNF267 
is already up-regulated in human cirrhotic liver 
tissue and might promote liver fibrosis through 
alteration of matrix degradation [11]. Since cir-
rhosis is the main risk factor for HCC develop-
ment, ZNF267 appears as promising target for 
both prevention as well as treatment of HCC in 
patients with chronic liver disease. 
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